Exhibit 99.2
COMPARABLE SALES BY PRODUCT CATEGORY
Worldwide Comparable Sales
(in millions)
(unaudited)
Product Category | 2013
Comparable
Sales | | 2014
Comparable
Sales | | Comparable %
Change | Comparable CC %
Change | Comparable $
Change | Comparable CC $
Change | Foreign Currency
Impact |
Heart Failure | $1,435 | | $1,469 | | 2% | 3% | $34 | $38 | -$5 |
Atrial Fibrillation | $975 | | $1,069 | | 10% | 11% | $94 | $111 | -$17 |
Neuromodulation | $426 | | $437 | | 3% | 3% | $11 | $13 | -$2 |
Cardiovascular | $1,317 | | $1,308 | | -1% | 1% | -$9 | $13 | -$23 |
Traditional CRM | $1,851 | | $1,817 | | -2% | 0% | -$34 | -$7 | -$27 |
Subtotal | $6,004 | | $6,100 | | 2% | 3% | $96 | $169 | -$73 |
Thoratec Pre-Acquisition | $503 | | $478 | | | | | | |
SJM As Reported | $5,501 | | $5,622 | | 2% | 4% | $121 | $195 | -$74 |
Note: Percentage changes are based on actual, non-rounded amounts and may not recalculate precisely. Data in this schedule have been rounded and, therefore, may not sum.
Worldwide Comparable Sales
(in millions)
(unaudited)
| | 2014 Comparable Sales | | 2015 Comparable Sales | | Comparable % Change | | Comparable $ Change |
Product Category | | Q1 | Q2 | Q3 | Q4 | FY14 | | Q1 | Q2 | Q3 | Q4 Est | FY15 Est | | Q1 | Q2 | Q3 | Q4 Est | FY Est | | Q1 | Q2 | Q3 | Q4 Est | FY Est |
Heart Failure | | $361 | $381 | $349 | $378 | $1,469 | | $372 | $389 | $365 | $368 | $1,494 | | 3% | 2% | 5% | -3% | 2% | | $11 | $8 | $16 | -$10 | $26 |
Atrial Fibrillation | | $257 | $263 | $258 | $290 | $1,069 | | $276 | $286 | $278 | $284 | $1,124 | | 8% | 9% | 7% | -2% | 5% | | $19 | $22 | $19 | -$6 | $55 |
Neuromodulation | | $99 | $107 | $107 | $124 | $437 | | $108 | $118 | $121 | $128 | $475 | | 9% | 10% | 13% | 3% | 9% | | $9 | $11 | $14 | $4 | $38 |
Cardiovascular | | $320 | $345 | $314 | $328 | $1,308 | | $302 | $316 | $291 | $303 | $1,211 | | -6% | -8% | -7% | -8% | -7% | | -$18 | -$29 | -$24 | -$26 | -$97 |
Traditional CRM | | $451 | $470 | $448 | $447 | $1,817 | | $408 | $430 | $408 | $371 | $1,618 | | -10% | -9% | -9% | -17% | -11% | | -$43 | -$40 | -$40 | -$76 | -$199 |
Subtotal | | $1,489 | $1,566 | $1,477 | $1,567 | $6,100 | | $1,466 | $1,539 | $1,463 | $1,454 | $5,922 | | -1% | -2% | -1% | -7% | -3% | | -$22 | -$27 | -$15 | -$114 | -$177 |
Thoratec Pre-Acquisition | | $126 | $118 | $106 | $128 | $478 | | $121 | $129 | $124 | $7 | $381 | | | | | | | | | | | | |
SJM As Reported | | $1,363 | $1,448 | $1,372 | $1,439 | $5,622 | | $1,345 | $1,410 | $1,339 | $1,447 | $5,541 | | -1% | -3% | -2% | 1% | -1% | | -$18 | -$38 | -$33 | $8 | -$81 |
Note: Percentage changes are based on actual, non-rounded amounts and may not recalculate precisely. Data in this schedule have been rounded and, therefore, may not sum.
Worldwide Comparable Sales
(in millions)
(unaudited)
| 2014 Comparable Sales | | 2015 Comparable Sales | | Comparable CC % Change | | Comparable CC $ Change | | Foreign Currency Impact |
Product Category | Q1 | Q2 | Q3 | Q4 | FY14 | | Q1 | Q2 | Q3 | Q4 Est | FY15 Est | | Q1 | Q2 | Q3 | Q4 Est | FY Est | | Q1 | Q2 | Q3 | Q4 Est | FY Est | | Q1 | Q2 | Q3 | Q4 Est | FY Est |
Heart Failure | $361 | $381 | $349 | $378 | $1,469 | | $372 | $389 | $365 | $368 | $1,494 | | 8% | 7% | 10% | 2% | 6% | | $27 | $28 | $34 | $6 | $95 | | -$16 | -$20 | -$17 | -$16 | -$70 |
Atrial Fibrillation | $257 | $263 | $258 | $290 | $1,069 | | $276 | $286 | $278 | $284 | $1,124 | | 16% | 18% | 17% | 5% | 14% | | $40 | $49 | $45 | $14 | $147 | | -$21 | -$26 | -$25 | -$20 | -$92 |
Neuromodulation | $99 | $107 | $107 | $124 | $437 | | $108 | $118 | $121 | $128 | $475 | | 14% | 17% | 19% | 9% | 14% | | $14 | $18 | $21 | $10 | $63 | | -$5 | -$7 | -$7 | -$6 | -$25 |
Cardiovascular | $320 | $345 | $314 | $328 | $1,308 | | $302 | $316 | $291 | $303 | $1,211 | | 2% | 1% | 2% | 0% | 1% | | $5 | $2 | $7 | $0 | $14 | | -$24 | -$32 | -$30 | -$26 | -$111 |
Traditional CRM | $451 | $470 | $448 | $447 | $1,817 | | $408 | $430 | $408 | $371 | $1,618 | | -3% | -1% | -1% | -11% | -4% | | -$15 | -$4 | -$4 | -$48 | -$72 | | -$29 | -$36 | -$36 | -$28 | -$127 |
Subtotal | $1,489 | $1,566 | $1,477 | $1,567 | $6,100 | | $1,466 | $1,539 | $1,463 | $1,454 | $5,922 | | 5% | 6% | 7% | -1% | 4% | | $72 | $93 | $100 | -$18 | $248 | | -$94 | -$121 | -$115 | -$95 | -$425 |
Thoratec Pre-Acquisition | $126 | $118 | $106 | $128 | $478 | | $121 | $129 | $124 | $7 | $381 | | | | | | | | | | | | | | | | | | |
SJM As Reported | $1,363 | $1,448 | $1,372 | $1,439 | $5,622 | | $1,345 | $1,410 | $1,339 | $1,447 | $5,541 | | 5% | 6% | 6% | 7% | 6% | | $73 | $80 | $80 | $99 | $332 | | -$91 | -$118 | -$113 | -$91 | -$413 |
Note: Percentage changes are based on actual, non-rounded amounts and may not recalculate precisely. Data in this schedule have been rounded and, therefore, may not sum.
U.S. Comparable Sales
(in millions)
(unaudited)
Product Category | | 2013
Comparable
Sales | | 2014
Comparable
Sales | | Comparable
% Change | | Comparable $
Change | |
| | | | | | | | | |
Heart Failure | | $943 | | $983 | | 4% | | $40 | |
| | | | | | | | | |
Atrial Fibrillation | | $377 | | $404 | | 7% | | $27 | |
| | | | | | | | | |
Neuromodulation | | $312 | | $297 | | -5% | | -$15 | |
| | | | | | | | | |
Cardiovascular | | $456 | | $469 | | 3% | | $13 | |
| | | | | | | | | |
Traditional CRM | | $899 | | $880 | | -2% | | -$19 | |
| | | | | | | | | |
| | | | | | | | | |
Subtotal | | $2,986 | | $3,032 | | 2% | | $46 | |
| | | | | | | | | |
| | | | | | | | | |
Thoratec Pre-Acquisition | | $390 | | $375 | | | | | |
| | | | | | | | | |
| | | | | | | | | |
SJM As Reported | | $2,596 | | $2,657 | | 2% | | $61 | |
| | | | | | | | | |
Note: Percentage changes are based on actual, non-rounded amounts and may not recalculate precisely. Data in this schedule have been rounded and, therefore, may not sum.
U.S. Comparable Sales
(in millions)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 2014 Comparable Sales | | 2015 Comparable Sales | | Comparable % Change | | Comparable $ Change |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Product Category | | Q1 | | Q2 | | Q3 | | Q4 | | FY14 | | Q1 | | Q2 | | Q3 | | Q4 Est | | FY15 Est | | Q1 | | Q2 | | Q3 | | Q4 Est | | FY Est | | Q1 | | Q2 | | Q3 | | Q4 Est | | FY Est |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Heart Failure | | $242 | | $251 | | $241 | | $249 | | $983 | | $259 | | $276 | | $263 | | $247 | | $1,043 | | 7% | | 10% | | 9% | | -1% | | 6% | | $17 | | $24 | | $22 | | -$2 | | $61 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Atrial Fibrillation | | $96 | | $98 | | $99 | | $112 | | $404 | | $116 | | $120 | | $123 | | $123 | | $481 | | 20% | | 22% | | 25% | | 10% | | 19% | | $20 | | $22 | | $25 | | $11 | | $77 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Neuromodulation | | $67 | | $71 | | $75 | | $84 | | $297 | | $75 | | $82 | | $90 | | $90 | | $337 | | 11% | | 15% | | 19% | | 8% | | 13% | | $8 | | $11 | | $15 | | $7 | | $40 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cardiovascular | | $114 | | $119 | | $115 | | $121 | | $469 | | $120 | | $121 | | $120 | | $112 | | $473 | | 6% | | 2% | | 4% | | -8% | | 1% | | $7 | | $3 | | $4 | | -$9 | | $4 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Traditional CRM | | $221 | | $224 | | $222 | | $213 | | $880 | | $208 | | $218 | | $210 | | $173 | | $810 | | -6% | | -3% | | -5% | | -18% | | -8% | | -$13 | | -$6 | | -$12 | | -$39 | | -$70 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Subtotal | | $740 | | $763 | | $752 | | $778 | | $3,032 | | $777 | | $817 | | $805 | | $745 | | $3,144 | | 5% | | 7% | | 7% | | -4% | | 4% | | $38 | | $53 | | $54 | | -$33 | | $112 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Thoratec Pre-Acquisition | | $96 | | $94 | | $86 | | $100 | | $375 | | $96 | | $104 | | $100 | | $6 | | $307 | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
SJM As Reported | | $644 | | $669 | | $666 | | $678 | | $2,657 | | $681 | | $713 | | $705 | | $739 | | $2,838 | | 6% | | 7% | | 6% | | 9% | | 7% | | $37 | | $43 | | $39 | | $61 | | $180 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Note: Percentage changes are based on actual, non-rounded amounts and may not recalculate precisely. Data in this schedule have been rounded and, therefore, may not sum.
International Comparable Sales
(in millions)
(unaudited)
Product Category | | 2013
Comparable
Sales | | 2014
Comparable
Sales | | Comparable %
Change | | Comparable CC %
Change | | Comparable $
Change | | Comparable CC $
Change | | Foreign Currency
Impact | |
Heart Failure | | $492 | | $486 | | -1% | | 0% | | -$6 | | -$1 | | -$5 | |
Atrial Fibrillation | | $598 | | $665 | | 11% | | 14% | | $67 | | $84 | | -$17 | |
Neuromodulation | | $114 | | $140 | | 23% | | 25% | | $26 | | $27 | | -$1 | |
Cardiovascular | | $861 | | $839 | | -3% | | 0% | | -$22 | | $0 | | -$23 | |
Traditional CRM | | $952 | | $938 | | -2% | | 1% | | -$14 | | $12 | | -$27 | |
| | | | | | | | | | | | | | | |
Subtotal | | $3,017 | | $3,067 | | 2% | | 4% | | $50 | | $123 | | -$73 | |
| | | | | | | | | | | | | | | |
Thoratec Pre-Acquisition | | $112 | | $102 | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
SJM As Reported | | $2,905 | | $2,965 | | 2% | | 5% | | $60 | | $134 | | -$74 | |
| | | | | | | | | | | | | | | |
Note: Percentage changes are based on actual, non-rounded amounts and may not recalculate precisely. Data in this schedule have been rounded and, therefore, may not sum.
International Comparable Sales
(in millions)
(unaudited)
| | | 2014 Comparable Sales | | 2015 Comparable Sales | | Comparable % Change | | Comparable $ Change |
Product Category | | | Q1 | | Q2 | | Q3 | | Q4 | | FY14 | | Q1 | | Q2 | | Q3 | | Q4 Est | | FY15 Est | | Q1 | | Q2 | | Q3 | | Q4 Est | | FY Est | | Q1 | | Q2 | | Q3 | | Q4 Est | | FY Est |
Heart Failure | | | $119 | | $130 | | $108 | | $129 | | $486 | | $114 | | $113 | | $102 | | $121 | | $451 | | -4% | | -12% | | -5% | | -6% | | -7% | | -$5 | | -$16 | | -$6 | | -$8 | | -$35 |
Atrial Fibrillation | | | $160 | | $166 | | $160 | | $179 | | $665 | | $160 | | $166 | | $155 | | $162 | | $643 | | 0% | | 0% | | -3% | | -9% | | -3% | | $0 | | $1 | | -$5 | | -$17 | | -$22 |
Neuromodulation | | | $32 | | $36 | | $32 | | $40 | | $140 | | $33 | | $36 | | $31 | | $38 | | $138 | | 4% | | 1% | | -4% | | -6% | | -1% | | $1 | | $0 | | -$1 | | -$3 | | -$2 |
Cardiovascular | | | $207 | | $226 | | $199 | | $207 | | $839 | | $182 | | $194 | | $171 | | $191 | | $738 | | -12% | | -14% | | -14% | | -8% | | -12% | | -$25 | | -$32 | | -$28 | | -$16 | | -$101 |
Traditional CRM | | | $231 | | $246 | | $226 | | $235 | | $938 | | $200 | | $212 | | $198 | | $198 | | $808 | | -13% | | -14% | | -13% | | -16% | | -14% | | -$30 | | -$34 | | -$29 | | -$37 | | -$130 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Subtotal | | | $749 | | $803 | | $726 | | $789 | | $3,067 | | $689 | | $722 | | $658 | | $709 | | $2,778 | | -8% | | -10% | | -9% | | -10% | | -9% | | -$59 | | -$81 | | -$69 | | -$80 | | -$289 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Thoratec Pre-Acquisition | | $30 | | $24 | | $20 | | $28 | | $102 | | $25 | | $24 | | $23 | | $1 | | $75 | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
SJM As Reported | | | $719 | | $779 | | $706 | | $761 | | $2,965 | | $664 | | $697 | | $634 | | $708 | | $2,703 | | -8% | | -10% | | -10% | | -7% | | -9% | | -$55 | | -$81 | | -$72 | | -$54 | | -$262 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Note: Percentage changes are based on actual, non-rounded amounts and may not recalculate precisely. Data in this schedule have been rounded and, therefore, may not sum.
International Comparable Sales
(in millions)
(unaudited)
| | 2014 Comparable Sales | | 2015 Comparable Sales | | Comparable CC % Change | | Comparable CC $ Change | | Foreign Currency Impact |
| | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Product Category | | Q1 | | Q2 | | Q3 | | Q4 | | FY14 | | Q1 | | Q2 | | Q3 | | Q4 Est | | FY15 Est | | Q1 | | Q2 | | Q3 | | Q4 Est | | FY Est | | Q1 | | Q2 | | Q3 | | Q4 Est | | FY Est | | Q1 | | Q2 | | Q3 | | Q4 Est | | FY Est |
Heart Failure | | $119 | | $130 | | $108 | | $129 | | $486 | | $114 | | $113 | | $102 | | $121 | | $451 | | 9% | | 3% | | 11% | | 6% | | 7% | | $11 | | $4 | | $12 | | $8 | | $35 | | -$16 | | -$20 | | -$17 | | -$16 | | -$70 |
Atrial Fibrillation | | $160 | | $166 | | $160 | | $179 | | $665 | | $160 | | $166 | | $155 | | $162 | | $643 | | 13% | | 16% | | 12% | | 2% | | 11% | | $21 | | $27 | | $20 | | $3 | | $70 | | -$21 | | -$26 | | -$25 | | -$20 | | -$92 |
Neuromodulation | | $32 | | $36 | | $32 | | $40 | | $140 | | $33 | | $36 | | $31 | | $38 | | $138 | | 21% | | 21% | | 17% | | 9% | | 17% | | $7 | | $8 | | $5 | | $4 | | $23 | | -$5 | | -$7 | | -$7 | | -$6 | | -$25 |
Cardiovascular | | $207 | | $226 | | $199 | | $207 | | $839 | | $182 | | $194 | | $171 | | $191 | | $738 | | -1% | | 0% | | 1% | | 4% | | 1% | | -$1 | | $0 | | $2 | | $9 | | $10 | | -$24 | | -$32 | | -$30 | | -$26 | | -$111 |
Traditional CRM | | $231 | | $246 | | $226 | | $235 | | $938 | | $200 | | $212 | | $198 | | $198 | | $808 | | -1% | | 1% | | 3% | | -4% | | 0% | | -$3 | | $2 | | $7 | | -$9 | | -$3 | | -$28 | | -$36 | | -$36 | | -$28 | | -$127 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Subtotal | | $749 | | $803 | | $726 | | $789 | | $3,067 | | $689 | | $722 | | $658 | | $709 | | $2,778 | | 5% | | 5% | | 6% | | 2% | | 4% | | $34 | | $40 | | $46 | | $15 | | $136 | | -$93 | | -$121 | | -$115 | | -$95 | | -$425 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Thoratec Pre-Acquisition | | $30 | | $24 | | $20 | | $28 | | $102 | | $25 | | $24 | | $23 | | $1 | | $75 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
SJM As Reported | | $719 | | $779 | | $706 | | $761 | | $2,965 | | $664 | | $697 | | $634 | | $708 | | $2,703 | | 5% | | 5% | | 6% | | 5% | | 5% | | $36 | | $37 | | $41 | | $38 | | $152 | | -$91 | | -$118 | | -$113 | | -$91 | | -$413 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Note: Percentage changes are based on actual, non-rounded amounts and may not recalculate precisely. Data in this schedule have been rounded and, therefore, may not sum.
The Company provides comparable sales growth and comparable, constant currency sales growth because St. Jude Medical management believes that in order to understand the Company’s short-term and long-term financial trends, investors may wish to consider the impact of the acquisition of Thoratec Corporation (“Thoratec”) in the fourth quarter of fiscal 2015 and foreign currency translation on net sales. St. Jude Medical management uses comparable sales growth and comparable, constant currency sales growth to forecast and evaluate the operational performance of the Company as well as to compare sales of current periods to prior periods.
In calculating comparable sales growth in its non-GAAP measures, the Company includes sales amounts previously reported by Thoratec for periods prior to St. Jude Medical’s acquisition of Thoratec. In calculating comparable constant currency sales growth in its non-GAAP measures, the company a) excludes the impact to net sales after translating net sales at prior period foreign currency exchange rates and b) includes Thoratec sales amounts for periods prior to St. Jude Medical’s acquisition of Thoratec. Comparable sales and comparable constant currency sales amounts have not been adjusted to eliminate historical product sales between St. Jude Medical and Thoratec because management believes that such adjustments are not material.
Non-GAAP financial measures used by the company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider non-GAAP measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.
